Journal
HAEMOPHILIA
Volume 19, Issue 3, Pages E151-E166Publisher
WILEY
DOI: 10.1111/hae.12095
Keywords
adjuvant therapy; bypassing therapy; haemophilia A; inhibitors; refractory bleeding
Categories
Funding
- Baxter Healthcare Corporation
- Baxter Bioscience
- Baxter
- Bayer
- CSL Behring
- Octapharma Pharmaceutical Companies
- Baxter Healthcare
- Bayer Healthcare
- NovoNordisk
- Pfizer
- Biogen Idec
- Octapharma
Ask authors/readers for more resources
In haemophilia patients with well-established high-titer inhibitors, even seemingly minor acute bleeding episodes or surgical procedures may become refractory to treatment and transform into limb- or life-threatening situations. In the absence of evidence-based treatment guidelines, this article presents 10 cases of difficult to control acute and surgical bleeding and offers consensus opinions regarding their management from a panel of experienced haemophilia treaters.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available